Healthcare provider profile · identity verified

Mark A. Lepsch, M.D.

Family Practice · CHARLOTTESVILLE, VA · NPI 1295718880

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	387	119
Rosuvastatin Calcium	Rosuvastatin Calcium	231	74
Amlodipine Besylate	Amlodipine Besylate	211	64
Lisinopril	Lisinopril	201	56
Losartan Potassium	Losartan Potassium	183	57
Metoprolol Succinate	Metoprolol Succinate	182	53
Levothyroxine Sodium	Levothyroxine Sodium	148	44
Tamsulosin Hcl	Tamsulosin Hcl	147	49
Omeprazole	Omeprazole	134	44
Gabapentin	Gabapentin	115	38
Fluoxetine Hcl	Fluoxetine Hcl	108	38
Hydrochlorothiazide	Hydrochlorothiazide	95	33
Allopurinol	Allopurinol	86	25
Finasteride	Finasteride	86	25
Simvastatin	Simvastatin	86	28
Furosemide	Furosemide	78	30
Trazodone Hcl	Trazodone Hcl	78	22
Metformin Hcl	Metformin Hcl	75	20
Albuterol Sulfate Hfa	Albuterol Sulfate	68	30
Escitalopram Oxalate	Escitalopram Oxalate	68	26
Eliquis	Apixaban	54	19
Metformin Hcl Er	Metformin Hcl	54	19
Pravastatin Sodium	Pravastatin Sodium	54	15
Sertraline Hcl	Sertraline Hcl	53	16
Meloxicam	Meloxicam	47	21
Fluticasone Propionate	Fluticasone Propionate	46	12
Montelukast Sodium	Montelukast Sodium	44	13
Pantoprazole Sodium	Pantoprazole Sodium	44	17
Carvedilol	Carvedilol	41	14
Prednisone	Prednisone	40	29
Zolpidem Tartrate	Zolpidem Tartrate	39	27
Azithromycin	Azithromycin	36	36
Ramipril	Ramipril	33	suppressed
Synthroid	Levothyroxine Sodium	31	11
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Famotidine	Famotidine	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	18
Xarelto	Rivaroxaban	29	suppressed
Clonazepam	Clonazepam	28	14
Mirtazapine	Mirtazapine	27	11
Ezetimibe	Ezetimibe	26	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Valacyclovir	Valacyclovir Hcl	24	15
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Ozempic	Semaglutide	23	suppressed
Atenolol	Atenolol	22	suppressed
Cephalexin	Cephalexin	21	20
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Methylprednisolone	Methylprednisolone	17	17
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Sod Sulf-Potass Sulf-Mag Sulf	Sodium, Potassium,mag Sulfates	16	16
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Baclofen	Baclofen	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Terbinafine Hcl	Terbinafine Hcl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Acyclovir	Acyclovir	13	11
Bupropion Xl	Bupropion Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	11
Glipizide	Glipizide	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Risperidone	Risperidone	13	suppressed
Amoxicillin	Amoxicillin	12	12
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	12	11
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error